TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...
Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells to target tumors. TIL therapy, now FDA-approved for solid tumors, shows ...
The OT-I mouse T-cell receptor (TCR) is thought to perfectly discriminate between lower-affinity self- and higher-affinity ...
The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...
Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
Xiangxue Life Sciences has agreed a strategic partnership with Guangzhou-based Damien Vaccines to co-develop in vivo TCR-T therapies, adding fresh momentum to one of the cell-therapy field’s most ...
The TCR repertoire provides a novel platform for investigating the modulation of the TME post-TACE and the underlying mechanisms governing tumor development and recurrence. Clarifying the distinctive ...
Studying T cells, the immune cells most responsible for responding to infections and cancers, just received a significant ...
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally. Often diagnosed at advanced stages, the therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback